Raising the bar on data and biosample sharing from AD/ADRD clinical trials
NIA’s increased funding for Alzheimer’s disease and related dementias (AD/ADRD) research has allowed the continued expansion and diversification of the drug development portfolio and translational infrastructure programs to help advance future therapeutics. Implementing best practices for sharing data, methods, and biosamples is at the core [...]
Alzheimer’s Breakthrough Ride
AD Knowledge Portal collaborator @btlamb organized a cross-country bike ride with the Alzheimer's Association. Read more from the IU School of Medicine. “I was thinking on this ride, we need to do something,” said Lamb, executive director of Stark Neurosciences Research Institute at Indiana University [...]
From ‘Where to FAIR’: Curating and Pre-processing the AddNeuroMed Dataset
By Zoë Leanza Sage Bionetworks Colin Birkenbihl At a recent conference, bioinformatician Colin Birkenbihl showcased his work on the AddNeuroMed (ANM) dataset. Birkenbihl, a PhD student at Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), painstakingly curated this extensive dataset to improve its [...]
‘A’ is for Agora: Leveraging Therapeutic Targets in an Undergraduate Course
University of Arizona is using AMP-AD consortium tools in new course A new course at the University of Arizona is using AMP-AD consortium tools to prototype treatments for Alzheimer’s disease. Called “Designing Drugs: From Chemistry to Cure” (or C2C), [...]